Cargando…

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial

Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F(2)-isoprostanes (F(2)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hulgan, Todd, Boger, M. Sean, Liao, Diana H., McComsey, Grace A., Wanke, Christine A., Mangili, Alexandra, Walmsley, Sharon L., McCreath, Heather, Milne, Ginger L., Sanchez, Stephanie C., Currier, Judith S., Lake, Jordan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058804/ https://www.ncbi.nlm.nih.gov/pubmed/24991090 http://dx.doi.org/10.1155/2014/803095

Ejemplares similares

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
por: Le, Catherine N., et al.
Publicado: (2017)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy
por: Offor, Obiageli, et al.
Publicado: (2018)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
por: Ammar, Farah F., et al.
Publicado: (2012)

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
por: Fernández-Caballero, Jose Ángel, et al.
Publicado: (2016)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
por: Machado, Lucas de Almeida, et al.
Publicado: (2019)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
por: Reigadas, Sandrine, et al.
Publicado: (2010)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension
por: McNeill, Jenna N., et al.
Publicado: (2023)

538. Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
por: Bedimo, Roger, et al.
Publicado: (2018)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells
por: Cervera, Ana M, et al.
Publicado: (2009)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

1570. Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study
por: Elion, Rick A, et al.
Publicado: (2023)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
por: Delelis, Olivier, et al.
Publicado: (2009)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Development of the patient-oriented research curriculum in child health (PORCCH)
por: Macarthur, Colin, et al.
Publicado: (2021)

Real-world impact of the COVID-19 pandemic on the assessment of anaesthesiology residents
por: Kealey, Alayne, et al.
Publicado: (2020)

Gauging treatment impact: The development of exposure variables in a large-scale evaluation study
por: Maccalla, Nicole M. G., et al.
Publicado: (2022)

Understanding the context and appreciating the complexity of evaluating the Diversity Program Consortium
por: Guerrero, Lourdes R., et al.
Publicado: (2022)

Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
por: Puthanakit, Thanyawee, et al.
Publicado: (2018)

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women
por: Cecchini, Diego M., et al.
Publicado: (2017)

Eicosanoids in reproduction /
Publicado: (1990)

Eicosanoids and cancer
por: Gomes, Renata Nascimento, et al.
Publicado: (2018)

The Role of Eicosanoids in Gynecological Malignancies
por: Smith, Paige G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sn5tif75gh59kq8g5r2mcgc5ev